Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): A report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM)

Leukemia Research

Volumn 37, Issue 6, 2013, Pages 637-640

  Bally, Cecile ^a,b   Thépot, Sylvain ^a,b   Quesnel, Bruno ^a,c   Vey, Norbert ^a,d   Dreyfus, Francois ^a,e   Fadlallah, Jehane ^b   Turlure, Pascal ^a,f   de Botton, Stephane ^a,g   Dartigeas, Caroline ^a,h   de Renzis, Benoit ^a,i   Itzykson, Raphael ^a   Fenaux, Pierre ^a,b   Adès, Lionel ^a,b  

^a Groupe Francophone des Myelodysplasies   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f Hopital Universitaire de Limoges   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h UNIVERSITÉ DE TOURS   (France)

ⁱ Hopital Universitaire de Clermont Ferrand   (France)

Author keywords

Azacitidine; Myelodysplastic syndromes; Therapy related MDS AML

Indexed keywords

AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TOXICITY; BONE MARROW BIOPSY; BREAST CARCINOMA; CANCER SURVIVAL; CHROMOSOME 7; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DRUG RESPONSE; FEMALE; GENE DELETION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SOLID TUMOR; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC PROTOCOLS; AZACITIDINE; COHORT STUDIES; FEMALE; FRANCE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; RADIATION INJURIES; SOCIETIES, MEDICAL; YOUNG ADULT;

EID: 84877062091     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.02.014     Document Type: Article

References (21)

1. Tefferi et A., Vardiman J.W. Myelodysplastic syndromes. N Engl J Med 2009, 361(November (19)):1872-1885.
2. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89(March (6)):2079-2088.
3. Kantarjian H.M., O'Brien S., Shan J., Aribi A., Garcia-Manero G., Jabbour E., et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007, 109(January (2)):265-273.
4. Moon J.H., Kim S.N., Kang B.W., Chae Y.S., Kim J.G., Baek J.H., et al. Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment. Ann Hematol 2010, 89(July (7)):681-689.
5. Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364(June (26)):2496-2506.
6. Godley et L.A., Larson R.A. Therapy-related myeloid leukemia. Semin Oncol 2008, 35(October (4)):418-429.
7. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10(March (3)):223-232.
8. Itzykson R., Thépot S., Quesnel B., Dreyfus F., Beyne-Rauzy O., Turlure P., et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011, 117(January (2)):403-411.
9. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.a.G., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51(2):189-199.
10. Thepot S., Itzykson R., Seegers V., Raffoux E., Quesnel B., Chait Y., et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 2010, 116(November (19)):3735-3742.
11. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(July (5)):937-951.
12. Klimek V.M., Dolezal E.K., Tees M.T., Devlin S.M., Stein K., Romero A., et al. Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes. Leuk Res 2012, 36(9):1093-1097.
13. Fianchi L., Criscuolo M., Lunghi M., Gaidano G., Breccia M., Levis A., et al. Outcome of therapy-related myeloid neoplasms treated with azacitidine. J Hematol Oncol 2012, 5(44).
14. Larson R.A., Wernli M., Le Beau M.M., Daly K.M., Pape L.H., Rowley J.D., et al. Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. Blood 1988, 72(October (4)):1333-1339.
15. Anderson J.E., Gooley T.A., Schoch G., Anasetti C., Bensinger W.I., Clift R.A., et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 1997, 89(7):2578-2585.
16. Yakoub-Agha I., de La Salmonière P., Ribaud P., Sutton L., Wattel E., Kuentz M., et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol 2000, 18(March (5)):963-971.
17. Kayser S., Döhner K., Krauter J., Köhne C.-H., Horst H.A., Held G., et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011, 117(February (7)):2137-2145.
18. Witherspoon R.P., Deeg H.J., Storer B., Anasetti C., Storb R., Appelbaum F.R. Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. JCO 2001, 19(8):2134-2141.
19. Chang C., Storer B.E., Scott B.L., Bryant E.M., Shulman H.M., Flowers M.E., et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007, 110(October (4)):1379-1387.
20. Damaj G, Salleron J, Robin M, Michallet M, Mohty M, Vigouroux S, Beguin Y, Garnier A, Lioure B, El Cheikh J, Fegueux N, Cornillon J, Adès L, François S, Rubio M-T, Park S, Garnier F, Fenaux P, Yakoub-Agha I. Impact of azacitidine (AZA) prior to allogeneic stem cell transplantation (allo-SCT) for myelodysplastic syndromes (MDS): a large-scale study on behalf of the SFGM-TC and GFM groups. [accessed 29.10.12]. https://ash.confex.com/ash/2011/webprogram/Paper36900.html.
21. Litzow M.R., Tarima S., Pérez W.S., Bolwell B.J., Cairo M.S., Camitta B.M., et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010, 115(March (9)):1850-1857.